Gail Ouellette, PhD, a geneticist and genetic counsellor, is president & Scientific Director of the Regroupement québécois des maladies orphelines (RQMO)/Quebec Coalition of Orphan Diseases. After doing a Ph.D. in molecular genetics and a postdoctoral fellowship in genetic epidemiology, she left the lab and the computer to become a genetic counsellor. During her time in genetics clinics, she started to work with patient organizations in Quebec, co-founded the RQMO in 2010 and set up a bilingual rare disease portal/help line service for rare diseases (iRARE Centre). She is also the creator of an educational website in genetics, genetiquesimplement.com/Genetics simply.
Agenda: Day 1 Oct 5, 2020
12:30 pm
12:30 pm
Panel Discussion: RARE DISEASE MARKET OUTLOOK
Paving the Way Forward for Rare Disease Therapies with Lessons Learned from COVID-19
Health Canada is preparing to implement a national strategy to help fund high-cost drugs for rare diseases by 2022–2023. How can you best prepare, and what can we learn from the COVID-19 vaccine journey? Inform your market access strategy with the experience of these market leaders. Establish your game plan by:
- Determining the types of partnerships and funding that will be key to the successful development of drugs for rare diseases
- Analyzing the impact of recently increased government funding on the overall treatment pipeline
- Visualizing potential safe and expeditious routes to commercialization for these medicines
Chart a course to succeed in the new market access model for rare disease therapies
Agenda: Day 2 Oct 6, 2020
